Research programme: HIV vaccine - Etubics Corporation

Drug Profile

Research programme: HIV vaccine - Etubics Corporation

Alternative Names: Preventative HIV-1 vaccine - Etubics

Latest Information Update: 29 Jul 2010

Price : $50

At a glance

  • Originator Etubics Corporation
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical HIV-1 infections

Most Recent Events

  • 29 Jul 2010 Preclinical development is ongoing in USA (Parenteral)
  • 27 Aug 2007 Preclinical trials in HIV-1 infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top